Telepathology Platform

Transforming Pathology with AI into the Digital Future

The ROSEAId cloud-based, AI centric platform empowers pathologists with advanced telepathology capabilities, enabling better, faster and more informed decisions on any device, anytime, anywhere ...in real-time!

Transforming Pathology with AI into the Digital Future

The ROSEAId cloud-based, AI centric platform empowers pathologists with advanced telepathology capabilities, enabling better, faster and more informed decisions on any device, anytime, anywhere ...in real-time!

Pathologists' Pain Points- ROSEAId’s Holistic Approach to Various Challenges

Pathologists face critical challenges that impact patient care and operational efficiencies. From navigating complex regional regulations to managing costly operations, practitioners fail with limited access to essential pathology tools and struggle with slow second opinions, leading to delayed diagnoses. The logistics of handling glass slides poses additional hurdles, affecting the security and affordability of their work. Simultaneously, data management coupled with high expenses for storage and retrieval, further aggravates the situation. Our innovative solutions aim to address these pressing issues, providing a streamlined and cost-effective approach to pathology practice, empowering healthcare professionals to enhance patient outcomes and optimize the standard of care.

Use Cases

ROSEAId, Inc. and the University of Texas Health Sciences Center (UTHealth), Houston, Texas, combine their expertise in a collaborative effort to optimize the precision and scope of pathology research, overcoming challenges posed by intricate data sets and diverse structural complexities. Details on a few mentioned use cases are provided below
  • ROSEAId explored Pancreatic Solid Lesions (PSL), training ML models with 1,200 images, refining image acquisition and ML processes. Followed by initiation in subsequent stages of single-cell identification, amended labeling, development of list of cell types and multi cell scenario capturing diverse combinations in pancreatic lesions. The model demonstrated its capabilities achieving high-rate accuracy in a blind test.
  • Preliminary Study Draft and Unified Model drafts titled ‘AI-based ROSEAId vs. Physician Interpretation in EUS-FNA’ showed 92.5% accuracy. A unified model approach improved analysis accuracy, extracting insights from sparse images.
  • Subepithelial Lesions (GI) and Lung Lesions (CT-Guided EBUS) comprehensive study was completed affirming the effectiveness of the unified model with 93.25% accuracy.

Why Choose ROSEAId for Your Pathology Solutions ?

Our use cases address the key pathological challenges, improving productivity, resolving quality issues, and mitigating the shortage of pathologists. The ROSEAId Telepathology AI-ROSE Platform is designed to address both adequacy determination and facilitating specimen triaging. The platform streamlines workflows by eliminating sample transfers, minimizes repeats and speeding up diagnostic timelines. Our telepathology platform resolves quality issues utilizing AI for Quality Assurance on Cytology WSI images and ROI. It provides High-Definition Imaging ensuring precision and comprehensive data for a variety of pathology services. The ROSEAId Telepathology Platform goes beyond clinical use, supporting quality assurance, education, and research initiatives to optimize your pathology practice with access to patient retrieval history records for retrospective review and critical examination for future references.

The Path Ahead

The AI-ROSE foundation is built on the ROSEAId Telepathology Platform, integrating ROSE and other AI features. It’s set to utilize the potential of our future plans outlined below:

  • First Quarter 2024, we will introduce Static Telepathology capabilities to our study partners.
  • Second Quarter 2024, ROSEAId will deploy a Dynamic Telepathology Platform and expand AI-ROSE to support more disease indications.
  • The platform will continue aligning Development Resources for Community Hospital Tests.
  • ROSEAId, Inc. remains steadfast in its commitment to pioneering advancements in the field of pathology. Our focus is on synchronizing production systems, satisfying the unique needs of remote communities.

Conclusion

ROSEAId, Inc. is positioned to lead the way, leveraging technology, innovation, and strategic collaborations to revolutionize pathology services. We have successfully developed AI-ROSE, a cloud-based platform for rapid onsite evaluation of EUS-FNA specimens. Ensuring high accuracy and global accessibility to ROSE services anytime, anywhere. Our vision is to automate the entire ROSE process, covering smear preparation, staining, image capture, adequacy determination, and potential diagnostic advice globally.